Institute for Clinical and Economic Review (ICER) Review of Disease-Modifying Therapies and Addendum Scope — Society Response
August 16, 2016
On July 18, the Institute for Clinical and Economic Review (ICER) announced that it would expand its review of multiple sclerosis disease-modifying therapies (DMTs) to include potential therapies for progressive MS. View the Society's comments; the public comment period for this addendum closed on August 12.
On July 15, the National MS Society submitted comments to ICER in response to its draft scope to review disease-modifying therapies used to treat relapsing-remitting MS.
ICER assesses the value of medications by considering price, how well a medication works compared to others, quality adjusted life years (QALYs) and other cost-effectiveness factors. Insurers may use ICER recommendations to develop their formularies, so ICER recommendations could potentially improve or limit access to MS medications. ICER plans to release a draft evidence report around November 22 which will open another public comment period. This will be followed by a public meeting to review the report in February 2017.
About Multiple Sclerosis
Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.